Altimmune Stock Soars 10.25% Ahead of MASH Trial Readout

On June 26, 2025, Altimmune's stock surged by 10.25% in pre-market trading, reflecting a significant bullish sentiment among investors.

Altimmune's stock has been gaining traction ahead of the anticipated readout from the MASH trial, scheduled for Thursday. Investors are eagerly awaiting the topline data, which is expected to provide crucial insights into the company's progress and potential future performance.

Analysts from H.C. Wainwright and Laidlaw & Company have both maintained a Buy rating on Altimmune, with price targets set at $15 and $16 respectively. These ratings come in the wake of the BX211 results, which have further bolstered investor confidence in the company's prospects.